HUMAN PRODUCTS

IQ-IDM development activity for safe and effective interventions for infectious disease in humans

Pre-clinical phase

Discovery phase

More information will follow soon

Rabies

Discovery phase

More information will follow soon

Pre-clinical phase

More information will follow soon

Human RSV

Virtually all children get an RSV infection by the time they are 2 years old. Most of the time RSV will cause a mild, cold-like illness, but it can also cause severe illness such as
- Bronchiolitis (inflammation of the small airways in the lung)
- Pneumonia (infection of the lungs)
Two to three out of every 100 infants with RSV infection may need to be hospitalized. Those who are hospitalized may require oxygen, IV fluids (if they aren’t eating and drinking), and mechanical ventilation (a machine to help with breathing).
Each year in the United States, an estimated 58,000-80,000 children younger than 5 years are hospitalized due to RSV infection. (CDC)

More than 90% of the world population is infected around puberty with EBV the virus that causes the so-called kissing disease
EBV can cause cancers like Hodgkin lymphoma/Burkitt lymphoma/ Nasopharyngeal carcinoma/Gastric carcinoma which together cause an estimated 200,000 deaths globally
EBV is also the causative agent of multiple sclerosis a severely debilitating inflammatory disease of the central nervous system affecting 2,8 million people globally
Current treatment of multiple sclerosis is targeted at the symptoms and not the cause requiring lifelong treatment and having little success in the final stages of the disease
IQ-IDM has identified small molecular compounds that pass the blood brain barrier that tackle the achilles heel of the causative agent EBV

Despite the availability of Dengue vaccines, the number of Dengue cases world-wide including the United states and Europe have significantly increased. About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year (WHO Dengue fact sheet April 2024).
While most pharmaceutical companies focus their development efforts on prophylactics for travellers to endemic areas, the development of therapeutic options for people living in endemic countries (96 million clinical manifestations per year) has been neglected and is sorely lagging.
IQ-IDM has identified small molecules for the treatment of Dengue haemorrhagic fever and Dengue arthralgia that can be manufactured at low cost.